BioSpace News Archive

Innovent Biologics, Inc. and UNION therapeutics A/S announced that the first Chinese healthy volunteer has been successfully dosed in the Phase I study of orismilast, a potential best-in-class PDE4 inhibitor in global clinical Phase II stage.

Seoul National University Bundang Hospital presented its preliminary study result of seizure monitoring for patients with epilepsy using SK Biopharmaceuticals’ multimodal wearable device at the American Epilepsy Society Annual Meeting 2022 in Nashville, Tennessee, December 2-6.

TherapeuticsMD, Inc. announced that it has entered into definitive agreements to license its products to an affiliate of Mayne Pharma Group Limited, an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, for commercialization in the United States.

$5 million raise to accelerate global market development & product development

Qilu Pharmaceutical announced that the results of the phase II study evaluating QL1604 plus chemotherapy as first-line treatment for patients with recurrent or metastatic cervical cancer were released on 4 December 2022 in oral presentation at the European Society for Medical Oncology Asia Congress 2022.

Protalix BioTherapeutics, Inc. announced that the Company will host a key opinion leader webinar on Fabry Disease and PRX-102 on Monday, December 5, 2022 at 8:30 a.m. Eastern Standard Time.

Telix Pharmaceuticals Limited announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession planning.